|
1
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mirimanoff RO, Gorlia T, Mason W, et al:
Radiotherapy and temozolomide for newly diagnosed glioblastoma:
recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3
phase III randomized trial. J Clin Oncol. 24:2563–2569. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ikushima H, Todo T, Ino Y, Takahashi M,
Miyazawa K and Miyazono K: Autocrine TGF-β signaling maintains
tumorigenicity of glioma-initiating cells through Sry-related
HMG-box factors. Cell Stem Cell. 5:504–514. 2009.
|
|
4
|
McFarland BC, Ma JY, Langford CP,
Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D and Benveniste EN:
Therapeutic potential of AZD1480 for the treatment of human
glioblastoma. Mol Cancer Ther. 10:2384–2393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sai K, Wang S, Balasubramaniyan V, et al:
Induction of cell-cycle arrest and apoptosis in glioblastoma
stem-like cells by WP1193, a novel small molecule inhibitor of the
JAK2/STAT3 pathway. J Neurooncol. 107:487–501. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ashizawa T, Miyata H, Ishii H, et al:
Antitumor activity of a novel small molecules STAT3 inhibitor
against a human lymphoma cell line with high STAT3 activation. Int
J Oncol. 38:1245–1252. 2011.PubMed/NCBI
|
|
7
|
Zhou Y, Liu F, Xu Q and Wang X: Analysis
of the expression profile of Dickkopf-1 gene in human glioma and
the association with tumor malignancy. J Exp Clin Cancer Res.
29:1382010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reardon DA, Fink KL, Mikkelsen T, et al:
Randomized phase II study of cilemgitide, an integrin-targeting
arginine-glycine-aspartic acid peptide, in recurrent glioblastoma
multiforme. J Clin Oncol. 26:5610–5617. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jo J, Schiff D and Purow B: Angiogenic
inhibition in high-grade gliomas: past, present and future. Expert
Rev Neurother. 12:733–747. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang CN, Huang YC, Yang DM, Kikuta K, Wei
KJ, Kubota T and Yang WK: A phase I/II clinical trial investigating
the adverse and therapeutic effects of a postoperative autologous
dendritic cell tumor vaccine in patients with malignant glioma. J
Clin Neurosci. 18:1048–1054. 2011. View Article : Google Scholar
|
|
11
|
Luptrawan A, Liu G and Yu JS: Dendritic
cell immunotherapy for malignant gliomas. Rev Recent Clin Trials.
3:10–21. 2008. View Article : Google Scholar
|
|
12
|
Ardon H, Van Gool SW, Verschuere T, et al:
Intergation of autologous dendritic cell-based immunotherapy in the
standard of care treatment for patients with newly diagnosed
glioblastoma: results of the HGG-2006 phase I/II trial. Cancer
Immunol Immunother. 61:2033–2044. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ardon H, Van Gool S, Lopes IS, et al:
Integration of autologous dendritic cell-based immunotherapy in the
primary treatment for patients with newly diagnosed glioblastoma
multiforme: a pilot study. J Neurooncol. 99:261–272. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oji Y, Suzuki T, Nakano Y, et al:
Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic
tumors. Cancer Sci. 95:822–827. 2004.
|
|
15
|
Bodey B, Siegel SE and Kaiser HE: MAGE-1,
a cancer/testis-antigen, expression in childhood astrocytomas as an
indicator of tumor progression. In vivo. 16:583–588.
2002.PubMed/NCBI
|
|
16
|
Liu G, Ying H, Zeng G, Wheeler CJ, Black
KL and Yu JS: HER-2, gp100, and MAGE-1 are expressed in human
glioblastoma and recognized by cytotoxic T cells. Cancer Res.
64:4980–4986. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Debinski W and Gibo DM: Molecular
expression analysis of restrictive receptor for interleukin 13, a
brain tumor-associated cancer/testis antigen. Mol Med. 6:440–449.
2000.PubMed/NCBI
|
|
18
|
Schmits R, Cochlovius B, Treitz G, et al:
Analysis of the antibody repertoire of astrocytoma patients against
antigens expressed by gliomas. Int J Cancer. 98:73–77. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yawata T, Nakai E, Park KC, et al:
Enhanced expression of cancer testis antigen genes in glioma stem
cells. Mol Carcinog. 49:532–544. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oba-Shinjo SM, Caballero OL, Jungbluth AA,
Rosemberg S, Old LJ, Simpson AJ and Marie SK: Cancer-testis (CT)
antigen expression in medulloblastoma. Cancer Immun.
8:72008.PubMed/NCBI
|
|
21
|
Syed ON, Mandigo CE, Killory BD, Canoll P
and Bruce JN: Cancer-testis and melanocyte-differentiation antigen
expression in malignant glioma and meningioma. J Clin Neurosci.
19:1016–1021. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sahin U, Koslowski M, Tureci O, et al:
Expression of cancer testis genes in human brain tumors. Clin
Cancer Res. 6:3916–3922. 2000.PubMed/NCBI
|
|
23
|
Renkvist N, Castelli C, Robbins PF and
Parmiani G: A listing of human tumor antigens recognized by T
cells. Cancer Immunol Immunother. 50:3–15. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nestle FO, Alijagic S, Gilliet M, et al:
Vaccination of melanoma patients with peptide- or tumor
lysate-pulsed dendritic cells. Nat Med. 4:328–332. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akiyama Y, Tanosaki R, Inoue N, et al:
Clinical response in Japanese metastatic melanoma patients treated
with peptide cocktail-pulsed dendritic cells. J Transl Med.
3:42005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tyagi P and Mirakhur B: MAGRIT: the
largest-ever phase III lung cancer trial aims to establish a novel
tumor-specific approach to therapy. Clin Lung Cancer. 10:371–374.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aoki M, Ueda S, Nishikawa H, et al:
Antibody responses against NY-ESO-1 and HER2 antigens in patients
vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1
and CHP-HER2 with OK-432. Vaccine. 27:6854–6861. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okada H, Kalinski P, Ueda R, et al:
Induction of CD8+ T-cell responses against novel
glioma-associated antigen peptides and clinical activity by
vaccinations with α-type 1 polarized dendritic cells and
polyinosinic-polycytidylic acid stabilized by lysine and
carboxymethylcellulose in patients with recurrent malignant glioma.
J Clin Oncol. 29:330–336. 2011.
|
|
29
|
Chi DD, Merchant RE, Rand R, et al:
Molecular detection of tumor-associated antigens shared by human
cutaneous melanomas and gliomas. Am J Pathol. 150:2143–2152.
1997.PubMed/NCBI
|
|
30
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hegi ME, Liu L, Herman LG, et al:
Correlation of O6-methylguanine methyltransferase (MGMT)
promoter methylation with clinical outcomes in glioblastoma and
clinical strategies to modulate MGMT activity. J Clin Oncol.
26:4189–4199. 2008.PubMed/NCBI
|
|
32
|
Quinn JA, Jiang SX, Reardon DA, et al:
Phase II trial of temozolomide plus O6-benzylguanine in
adults with recurrent, temozolomide-resistant maliganant glioma. J
Clin Oncol. 27:1262–1267. 2009.PubMed/NCBI
|
|
33
|
Natsume A, Wakabayashi T, Tsujimura K, et
al: The DNA demethylating agent 5-aza-2′-deoxycytidine activates
NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer.
122:2542–2553. 2008.
|
|
34
|
Low J, Dowless M, Shiyanova T, et al:
Knockdown of cancer testis antigens modulates neural stem cell
marker expression in glioblastoma tumor stem cells. J Biomol
Screen. 15:830–839. 2010. View Article : Google Scholar : PubMed/NCBI
|
